Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Sotorasib Tablets Market Poised To Hit $3.39 Billion By 2030 With A 12% CAGR
The sotorasib tablets market has shown significant growth in recent years. It is projected to expand from $1.92 billion in 2025 to $2.16 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.3%. This past growth can be ascribed to factors such as an increasing diagnosis rate for non-small cell lung cancer, advancements in KRAS mutation research, regulatory approvals for targeted oncology drugs, an expansion of molecular diagnostic capabilities, and a rise in oncology clinical trials.
The sotorasib tablets market is projected to experience substantial expansion in the coming years, reaching a valuation of $3.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.0%. This anticipated growth during the forecast period is fueled by several factors, including the increased development of next-generation KRAS inhibitors, the proliferation of combination therapy strategies, the extension of targeted treatments to encompass more cancer indications, the wider application of real-world evidence studies, and the growing embrace of oncology precision medicine. Key developments shaping the market during this period involve the increasing uptake of KRAS G12C inhibitor therapies, a heightened emphasis on targeted treatments for lung cancer, the expanding use of oral oncology medications, broader implementation of companion diagnostic testing, and improved surveillance of resistance mechanisms.
Get A Free Sample Report With In-Depth Market Insights:
Sotorasib Tablets Market Demand Drivers Opening New Revenue Streams
The increasing occurrence of cancer is projected to fuel the expansion of the sotorasib tablets market moving forward. Cancer encompasses a range of illnesses characterized by the uncontrolled proliferation of abnormal cells, which infiltrate tissues and can metastasize to other body parts. This rise in cancer incidence is attributed to an aging populace, as advanced age represents the primary risk factor for developing most cancer types, with the majority of diagnoses occurring in individuals over 65 years. Sotorasib tablets function by specifically and permanently deactivating the KRAS G12C mutation, thereby preventing the unchecked growth of cells in patients with advanced solid tumors, especially non-small cell lung cancer. For instance, the World Health Organization, a Switzerland-based international entity focused on global health policy and public health initiatives, reported in February 2024 that more than 35 million new cancer cases are anticipated by 2050, signifying a 77% increase from the approximately 20 million cases estimated in 2022. Consequently, the growing prevalence of cancer is propelling the sotorasib tablets market forward. The increasing demographic of older individuals is anticipated to boost the expansion of the sotorasib tablets market moving forward. The geriatric population denotes adults typically aged 65 and above, who may undergo age-related physiological, psychological, and social transformations. This growth in the older population largely stems from extended life expectancy, as progress in healthcare, nutrition, and living standards enables more people to live longer, leading to a greater proportion of seniors in the populace. Sotorasib tablets aid the geriatric demographic by specifically targeting KRAS G12C-mutated cancers, providing a precise treatment approach that addresses age-associated susceptibilities and enhances treatment results for older patients. For example, the UK Parliament’s House of Commons Library, a UK-based government administrative body, stated in July 2024 that in 2022, the UK had 12.7 million individuals aged 65 or older, making up 19% of the total population. This figure is predicted to climb to 22.1 million by 2072, representing 27% of the population. Therefore, the expanding geriatric population is propelling the growth of the sotorasib tablets market.
Sotorasib Tablets Market Segmentation: How Does The Market Break Down By Category?
The sotorasib tablets market covered in this report is segmented –
1) By Dosage Form: 40 Milligrams (Mg) Tablets, 120 Milligrams (Mg) Tablets, 240 Milligrams (Mg) Tablets, Other Dosage Forms
2) By Patient Demographics: Adolescents, Adult, Senior Adults
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Non-Small Cell Lung Cancer, Colorectal Cancer, Other Applications
5) By End-User: Hospitals, Oncology Centers, Clinics, Other End-Users
Sotorasib Tablets Market Trends Powering Strategic Industry Growth
Leading companies within the sotorasib tablets market are prioritizing the development of innovative therapies, such as combination treatments, to enhance efficacy and overcome resistance. Combination treatments involve administering two or more drugs simultaneously to target cancer through multiple mechanisms, which helps increase treatment effectiveness, overcome or delay drug resistance, reduce the likelihood of cancer recurrence, and improve overall patient outcomes and quality of life. For example, in January 2025, Amgen Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) approval for sotorasib combined with panitumumab for treating adult patients with KRAS G12C–mutated metastatic colorectal cancer (mCRC) who had previously undergone standard chemotherapy. This approval was granted based on the results of the Phase 3 CodeBreaK 300 study, which showed that this combination more than doubled progression-free survival compared to the investigator’s preferred standard-of-care therapy, thereby providing a significant new option for individuals with this difficult-to-manage cancer. Sotorasib is a first-in-class, oral KRAS G12C inhibitor that functions by selectively targeting and stabilizing the mutant KRAS protein in its inactive state, consequently blocking cancer cell growth and signaling pathways driven by this mutation.
Sotorasib Tablets Market Competitive Overview And Top Companies
Major companies operating in the sotorasib tablets market are Amgen Inc.
View The Full Sotorasib Tablets Market Report:
Sotorasib Tablets Market Top Region By Revenue And Market Share
North America was the largest region in the sotorasib tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotorasib tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
